TY - JOUR
T1 - Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer
AU - Mrugala, Maciej M.
AU - Kim, Bryan
AU - Sharma, Akanksha
AU - Johnson, Natalie
AU - Graham, Carrie
AU - Kurland, Brenda F.
AU - Gralow, Julie
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/10
Y1 - 2019/10
N2 - Metastatic breast cancer frequently leads to brain metastases and, less commonly, leptomeningeal carcinomatosis (LC). Once cerebrospinal fluid involvement occurs, the prognosis is poor. There are limited treatment options available, but none offer significant survival benefit. Methotrexate, given systemically at high doses (3.5-8 gm/m2), achieves cytotoxic concentrations in the CSF and has been shown to prolong survival in patients with LC. Intrathecal liposomal cytarabine has been shown to increase time to neurologic progression in patients with breast cancer and LC. The combination of these 2 agents in LC has not been studied extensively. Here, we present the results of the phase II study with this combination showing promising efficacy and very good tolerability.
AB - Metastatic breast cancer frequently leads to brain metastases and, less commonly, leptomeningeal carcinomatosis (LC). Once cerebrospinal fluid involvement occurs, the prognosis is poor. There are limited treatment options available, but none offer significant survival benefit. Methotrexate, given systemically at high doses (3.5-8 gm/m2), achieves cytotoxic concentrations in the CSF and has been shown to prolong survival in patients with LC. Intrathecal liposomal cytarabine has been shown to increase time to neurologic progression in patients with breast cancer and LC. The combination of these 2 agents in LC has not been studied extensively. Here, we present the results of the phase II study with this combination showing promising efficacy and very good tolerability.
KW - Breast cancer metastasis
KW - High-dose methotrexate
KW - Intrathecal chemotherapy
KW - Leptomeningeal carcinomatosis
KW - Liposomal cytarabine
UR - http://www.scopus.com/inward/record.url?scp=85066430843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066430843&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2019.04.004
DO - 10.1016/j.clbc.2019.04.004
M3 - Article
C2 - 31175053
AN - SCOPUS:85066430843
SN - 1526-8209
VL - 19
SP - 311
EP - 316
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 5
ER -